March 5, 2024

Genomic Biomarker Market Size to Grow US$ 8.6 Billion By 2030

The global genomic biomarker market size was valued at US$ 4.5 billion in 2021 and is anticipated to grow US$ 8.6  billion by 2030, registering a compound annual growth rate (CAGR) of 7.46% from 2022 to 2030.

Genomic Biomarker Market Size 2022 To 2030

The genomic biomarker market report covering various industry elements and growth trends helpful for predicting the market’s future.

The study provides a strong base for the genomic biomarker market to be segmented into different segments. In fact, the study also covers the maximum market share during the assessment period by 2030.

This study is based on the partners that are highly competitive, key players as well as their market revenue in the forecast years of 2022 to 2030. There is also a strong focus on product revenues, sales, product categories and even the products that are experiencing the most traction. In this manner, the genomic biomarker report also speaks about the effectiveness of this market along with its growth during the forecast period of 2030. Other major attributes of the genomic biomarker market have been studied and analysed across many developments.

Report Scope of the Genomic Biomarker Market

Report Coverage Details
Market Size in 2022 USD 4.84 Billion
Market Size by 2030 USD 8.6 Billion
Growth Rate from 2022 to 2030 CAGR of 7.46%
Base Year 2021
Forecast Period 2022 to 2030
Segments Covered Type, Disease Indication, End-User, and Geography

Research Approach

The comprehensive report on the global genomic biomarker market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products. Following this, the report provides detailed explanation of objectives of this study and laid down by accredited agencies in the purview of research in the global genomic biomarker market.

It is followed by market introduction, market dynamics, and an overview of the global market, which includes analysis of market drivers, restraints, and trends pertaining to the global market. Furthermore, Y-o-Y growth analysis with elaborated insights has been provided in order to understand the Y-o-Y growth trend of the global market.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller sections. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

Key Players are  Almac Group, Cancer Genetics Inc, Eurofins Scientific, Thermo Fisher Scientific Inc, Aepodia SA, Epigenomics AG, US Biomarkers Inc., Roche Diagnostics, Myriad Genetics, Bio-Rad Laboratories

Market Segmentations

By Type 

  • Predictive Biomarkers
  • Prognostic Biomarkers

By Disease Indication

  • Oncology
  • Cardiovascular Diseases
  • Neurological Diseases
  • Renal Disorders
  • Others

By End-User 

  • Hospitals
  • Diagnostic Centers
  • Others

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa (MEA)

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Genomic Biomarker Market 

5.1. COVID-19 Landscape: Genomic Biomarker Industry Impact

5.2. COVID 19 – Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Genomic Biomarker Market, By Type

8.1. Genomic Biomarker Market, by Type, 2022-2030

8.1.1 Predictive Biomarkers

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Prognostic Biomarkers

8.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Genomic Biomarker Market, By Disease Indication

9.1. Genomic Biomarker Market, by Disease Indication, 2022-2030

9.1.1. Oncology

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. Cardiovascular Diseases

9.1.2.1. Market Revenue and Forecast (2017-2030)

9.1.3. Neurological Diseases

9.1.3.1. Market Revenue and Forecast (2017-2030)

9.1.4. Renal Disorders

9.1.4.1. Market Revenue and Forecast (2017-2030)

9.1.5. Others

9.1.5.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Genomic Biomarker Market, By End-User 

10.1. Genomic Biomarker Market, by End-User, 2022-2030

10.1.1. Hospitals

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. Diagnostic Centers

10.1.2.1. Market Revenue and Forecast (2017-2030)

10.1.3. Others

10.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Genomic Biomarker Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Type (2017-2030)

11.1.2. Market Revenue and Forecast, by Disease Indication (2017-2030)

11.1.3. Market Revenue and Forecast, by End-User (2017-2030)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Type (2017-2030)

11.1.4.2. Market Revenue and Forecast, by Disease Indication (2017-2030)

11.1.4.3. Market Revenue and Forecast, by End-User (2017-2030)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Type (2017-2030)

11.1.5.2. Market Revenue and Forecast, by Disease Indication (2017-2030)

11.1.5.3. Market Revenue and Forecast, by End-User (2017-2030)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Type (2017-2030)

11.2.2. Market Revenue and Forecast, by Disease Indication (2017-2030)

11.2.3. Market Revenue and Forecast, by End-User (2017-2030)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Type (2017-2030)

11.2.4.2. Market Revenue and Forecast, by Disease Indication (2017-2030)

11.2.4.3. Market Revenue and Forecast, by End-User (2017-2030)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Type (2017-2030)

11.2.5.2. Market Revenue and Forecast, by Disease Indication (2017-2030)

11.2.5.3. Market Revenue and Forecast, by End-User (2017-2030)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Type (2017-2030)

11.2.6.2. Market Revenue and Forecast, by Disease Indication (2017-2030)

11.2.6.3. Market Revenue and Forecast, by End-User (2017-2030)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Type (2017-2030)

11.2.7.2. Market Revenue and Forecast, by Disease Indication (2017-2030)

11.2.7.3. Market Revenue and Forecast, by End-User (2017-2030)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Type (2017-2030)

11.3.2. Market Revenue and Forecast, by Disease Indication (2017-2030)

11.3.3. Market Revenue and Forecast, by End-User (2017-2030)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Type (2017-2030)

11.3.4.2. Market Revenue and Forecast, by Disease Indication (2017-2030)

11.3.4.3. Market Revenue and Forecast, by End-User (2017-2030)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Type (2017-2030)

11.3.5.2. Market Revenue and Forecast, by Disease Indication (2017-2030)

11.3.5.3. Market Revenue and Forecast, by End-User (2017-2030)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Type (2017-2030)

11.3.6.2. Market Revenue and Forecast, by Disease Indication (2017-2030)

11.3.6.3. Market Revenue and Forecast, by End-User (2017-2030)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Type (2017-2030)

11.3.7.2. Market Revenue and Forecast, by Disease Indication (2017-2030)

11.3.7.3. Market Revenue and Forecast, by End-User (2017-2030)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Type (2017-2030)

11.4.2. Market Revenue and Forecast, by Disease Indication (2017-2030)

11.4.3. Market Revenue and Forecast, by End-User (2017-2030)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Type (2017-2030)

11.4.4.2. Market Revenue and Forecast, by Disease Indication (2017-2030)

11.4.4.3. Market Revenue and Forecast, by End-User (2017-2030)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Type (2017-2030)

11.4.5.2. Market Revenue and Forecast, by Disease Indication (2017-2030)

11.4.5.3. Market Revenue and Forecast, by End-User (2017-2030)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Type (2017-2030)

11.4.6.2. Market Revenue and Forecast, by Disease Indication (2017-2030)

11.4.6.3. Market Revenue and Forecast, by End-User (2017-2030)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Type (2017-2030)

11.4.7.2. Market Revenue and Forecast, by Disease Indication (2017-2030)

11.4.7.3. Market Revenue and Forecast, by End-User (2017-2030)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Type (2017-2030)

11.5.2. Market Revenue and Forecast, by Disease Indication (2017-2030)

11.5.3. Market Revenue and Forecast, by End-User (2017-2030)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Type (2017-2030)

11.5.4.2. Market Revenue and Forecast, by Disease Indication (2017-2030)

11.5.4.3. Market Revenue and Forecast, by End-User (2017-2030)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Type (2017-2030)

11.5.5.2. Market Revenue and Forecast, by Disease Indication (2017-2030)

11.5.5.3. Market Revenue and Forecast, by End-User (2017-2030)

Chapter 12. Company Profiles

12.1. Almac Group

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Cancer Genetics Inc

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Eurofins Scientific

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Thermo Fisher Scientific Inc

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Aepodia SA

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Epigenomics AG

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. US Biomarkers Inc.

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Roche Diagnostics

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Myriad Genetics

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Bio-Rad Laboratories

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

Why should you invest in this report?

If you are aiming to enter the global genomic biomarker market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for genomic biomarker are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2022-2030 so that you can plan your strategies to enter this market accordingly.

Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.

Request a Sample Copy of This Report @ https://www.precedenceresearch.com/sample/2231

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Email: sales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Prathamesh

I have completed my education in Bachelors in Computer Application. A focused learner having a keen interest in the field of digital marketing, SEO, SMM, and Google Analytics enthusiastic to learn new things along with building leadership skills.

View all posts by Prathamesh →

Leave a Reply

Your email address will not be published. Required fields are marked *